2018-Present 

NOW RECRUITING PATIENTS! 

Samsung Bioepis Co. Ltd
A Phase III Randomized, Double-Masked, Parallel Group, Multicentre Study to Compare the Efficacy, Safety, Pharmacokinetics, Immunogenicity between SB11 (proposed ranibizuamb biosimilar) and Lucentis in subjects with Neovascular Age-related Macular Degeneration

Please call 516-466-0390 if you are interested in participating in the Samsung Bioepis trial.

2016-2017

Genentech/Roche
Stairway: Simultaneous Blockage of Angiopoientin-2 VEGF-A With the Bispecific Antibody RO6867461 (RG7716) for Extended Durability in the Treatment of Neovascular Age-Related Macular Degeneration

2016-Present

Regeneron
A Randomized, Double-Masked, Active-Controlled, Phase 2 Study of the Efficacy, Safety and Tolerability of Repeated Doses of Intravitreal REGEN910-3 in Patients with Neovascular Age-Related Macular Degeneration

2016-Present

Regeneron
A Randomized, Double-Masked, Active-Controlled, Phase 2 Study of the Efficacy, Safety and Tolerability of Repeated Doses of Intravitreal REGEN910-3 in Patients with Diabetic Macular Edema

2016-Present

OHR Pharmaceuticals
OHR1601: A Phase III Study of the Effiacay and Saftey of Squalamine Lactate Ophthalmic Solution, 0.2% Twice Daily in Subjects with Neovascular Age-Related Macular Degeneration

2015-Present

Genentech, Inc.
A Multiple-Center, Multiple-Dose and Regimen, Randomized, Active Comparator Controlled, Double- Masked, Parallel Group, 36 Week Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO6867461 Administered Intravitreally in Patients with Choroidal Neovascularization Secondary to Age Related Macular Degeneration

2015-Present

Allergan Pharmaceuticals
Safety and Efficacy of Abicipar Pegol(AGN-150998) in Patients with Neovascular Age-Related Degeneration

2015-2017

Regeneron Pharmaceuticals, Inc.
A Phase 2, Double-Masked, Randomized, Controlled, Multiple-Dose, Regimen- Ranging Study of the Efficacy and Safety of Intravitreal REGN2176-3 in Patients with Neovascular Age-Related Macular Degeneration

2014-Present

Genentech, Inc.
A Phase III, Multicenter, Randomized, Double-Masked, Sham-controlled Study to Assess the Efficacy and Safety of Lampalizumab Administered Intravitreally to Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration

2014-2015 Allergan Pharmaceuticals Evaluation of Abicipar Pegol(AGN-150998) in Patients with Decreased Vision Due to Diabetic Macular Edema 2014-2015 Penn State Score 2: Study of Comparative Treatments for Retinal Vein Occlusion 2

2013-2016 Acucela, Inc. A Phase 2b/3 Multicenter, Randomized, Double-Masked, Dose-Ranging Study Comparing the Efficacy and Safety of Emixustat Hydrochloride (ACU-4429) With Placebo for the Treatment of Geographic Atrophy Associated With Dry Age-Related Macular Degeneration

2012–2014 Allergan Pharmaceuticals A Multi-center, Open-label, Randomized Study Comparing the Efficacy and Safety of 700ug Dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS) to Ranibizumab in Patients with Diabetic Macular Edema

2011-2013 Barnes Retina Institute CRAVE: Comparison of Anti-VEGF Agents in the Treatment of Macular Edema from Retinal Vein Occlusion

2010-2013 Investigator Sponsored Trial - in association with Allergan Pharmaceuticals A Comparative Study of Initial Ozurdex (dexamethasone implant) versus Avastin (bevacizumab) in the Treatment of Macular Edema Following Central Retinal Vein Occlusion (CRVO)

2009-2010 Genentech, Inc. A Phase III, Double Masked, Multicenter, Randomized, Active Treatment-Controlled Study of the Efficacy and Safety of 0.5 mg and 2.0 mg Ranibizumab Adminsitered Monthly or on an As-Needed-Basis in Patients with Subfoveal Neovascular AMD

2008-2010 Genentech, Inc. An Open-label, Multicenter Extension Study to Evaluate the Safety and Tolerability of Ranibizumab in Subjects with Choroidal Neovascularization Secondary to Age-Related Macular Degeneration or Macular Edema Secondary to Retinal Vein Occlusion Who Have Completed the Treatment Phase of a Genentech-Sponsored Ranibizumab Study

2008-2012 National Eye Institute CATT: Lucentis-Avastin Trial (Comparison of Age-Related Macular Degeneration Treatments Trials)

2007-2009 Genentech, Inc. A Phase III, Multicenter, Randomized, Sham Injection-Controlled Study Of The Efficacy and Safety of Ranibizumab Injection Compared With Sham In Subjects With Macular Edema Secondary to Central Retinal Vein Occlusion

2007-2009 Genentech, Inc. A Phase III, Multicenter, Randomized, Sham Injection-Controlled Study Of The Efficacy and Safety of Ranibizumab Injection Compared With Sham In Subjects With Macular Edema Secondary to Branch Retinal Vein Occlusion

2007 2013 Investigator Sponsored Trial - in association with Genentech, Inc. A Phase I/II Study Comparing the Treatment of Clinically Significant Diabetic Macular Edema (CSDME) with 0.5mg Ranibizumab, 1.0mg Ranibizumab and 2.0mg Ranibizumab

2007-2009 Allergan Pharmaceuticals A 6-Month, Single-Masked, Multicenter, Randomized, Controlled Study to Assess the Safety and Efficacy of 700mcg Dexamethasone Posterior Segment Drug Delivery System Applicator System as Adjunctive Therapy to Lucentis Compared with Lucentis Alone in the Treatment of Patients with Choroidal Neovascularization Secondary to Age-Related Macular Degeneration

2006-2007 Regeneron Pharmaceuticals A Randomized, Controlled Study of the Safety, Tolerability and Biological Effect of Repeated Intravitreal Administration of VEGF Trap in patients with Neovascular Age-Related Macular Degeneration

2005-2007 Genentech, Inc. A Phase IIIb, Multicenter Study to Evaluate the Safety and Tolerability of Ranibizumab in Naïve and Previously Treated Subjects with Choroidal Neovascularization Secondary to Age-Related Macular Degeneration

2005-2008 Genentech, Inc. An Open-label, Multicenter Extension Study to Evaluate the Safety and Tolerability of Ranibizumab in Subjects with Choroidal Neovascularization Secondary to Age-Related Macular Degeneration Who Have Completed the Treatment Phase of a Genentech-Sponsored Ranibizumab Study

2005-2006 Acuity Pharmaceuticals A Phase II, Randomized, Double-Masked, Controlled, Dose Comparison Study of Cand5 for Intravitreal Injection for the Treatment of Subfoveal Choroidal Neovascularization Associated with Wet Age-Related Macular Degeneration

2004-2006 Genaera Corporation A Phase 2, Multi-Center, Randomized, Masked, Controlled, Study of Squalamine Lactate for the Treatment of Subfoveal Choroidal Neovascularization Associated with Age-Related Macular Degeneration

2004-2005 Eyetech Pharmaceuticals A Phase II Prospective, Randomized, Double-Masked, Sham-Controlled, Dose-Ranging, Multi-Center Trial to Assess the Effect of Pegaptanib Sodium on Foveal Thickening in Patients with Exudative Subfoveal Age-Related Macular Degeneration

2004-2008 Alcon Research Posterior Juxtascleral Administrations of Anecortave Acetate for Depot Suspension versus Sham Administration in Patients at Risk for Developing Sight-Threatening Choroidal Neovascularization Due to Exudative Age-Related Macular Degeneration

2003-2006 Genentech,Inc. FOCUS Study Multiple-dose Intravitreal Injections of rhuFab V2 in Combination with Verteporfin Photodynamic Therapy in Subjects with Neovascular Age-Related Macular Degeneration

2003-2006 Genetech,Inc. MARINA Study. rhuFab V2 in Subjects with Minimally Classic or Occult Subfoveal Neovascular Age-Related Macular Degeneration

2002-2005 Alcon Research Posterior Juxtascleral Injections of Anecortave Acetate versus Visudyne in Patients with Subfoveal Exudative Age-Related Macular Degeneration Eligible for Initial Treatment with Photodynamic Therapy using Visudyne

2001-2006 Eyetech Pharmaceuticals Intravitreal Injections of EYE001 (Anti-VEGF Pegylated Aptamer) Given Every 6 Weeks for 54 weeks in patients with Age-Related Macular Degeneration

2000-2002 CIBA Vision PKC412 in Patients with Diabetic Macular Edema (VEGF Protein Kinase Inhibitor)

1999-2002 ISTA Pharmaceuticals (formerly Advanced Corneal Systems) Vitrase (Hyaluronidase) for Ophthalmic Intravitreal Injection for Clearance of Severe Vitreous Hemorrhage

1999-2001 Miravant Pharmaceuticals Tin EthylEtiopurpurin (SnET2)Photodynamic Therapy in the Treatment of Subfoveal Choroidal Neovascularization Associated with Age Related Macular Degeneration